Herbert Irving Comprehensive Cancer Center
Investigator
Rachael Safyan, MD
Phone
646-317-6085
Email
rs2263@cumc.columbia.edu

Dr. Rachael Safyan is a medical oncologist specializing in the treatment of gastrointestinal malignancies, with an emphasis on pancreatic and colorectal cancers. She graduated Phi Beta Kappa and summa cum laude from Barnard College of Columbia University, having majored in Neuroscience and Behavior, and received her medical degree from New York University School of Medicine. Dr. Safyan completed an internship in Internal Medicine at Boston Medical Center and a residency in Internal Medicine at the University of Washington, where she was inducted into the Gold Humanism Honor Society. She was then selected to serve as a Chief Resident and Acting Instructor at the University of Washington Medical Center. Dr. Safyan completed her fellowship in Hematology and Medical Oncology at New York-Presbyterian/Columbia University Medical Center, where she was appointed Chief Fellow. During that time, she was awarded a Conquer Cancer Foundation/American Society of Clinical Oncology (ASCO) Young Investigator Award for her work in pancreatic cancer.

Dr. Safyan is actively involved in clinical and translational research. Her focus is on the development and clinical evaluation of novel therapies for patients with gastrointestinal malignancies, particularly colorectal and pancreatic cancers. In addition, she is passionate about medical education and is an Assistant Program Director of the Hematology/Oncology Fellowship. She is also the Director of the Oncology Subinternship and a lecturer for the medical school second-year oncology course The Body in Health and in Disease.

Dr. Safyan’s goal as a clinician and researcher is to improve upon existing treatment strategies. She is proud to offer compassionate and personalized care to each patient alongside CUMC’s dedicated multidisciplinary team.


Clinical Studies Managed By This Investigator:
Condition Study Title
Gastrointestinal [ CLOSED ] Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer